TYPE 2 DIABETES MELLITUS


Presenter: SHUMBUSHO GLORIA, IM resident year 2 Supervisor: BAZATSINDA TONY Consultant Physician

July 2019

OUTLINE

- Introduction
- Pathophysiology
- Clinical manifestations
- Diagnosis
- Complications
- Management of DM
- Take home message

What is diabetes?



Rambiritch et al 2007. Southern Medical Journal. 100(11):1132-1136

Introduction...


- Diabetes mellitus has been known for over 3000 years.
- Diabetes, a greek word means passing though; a large discharge of urine,
- Mellitus means pleasant tasting, honey.
- T2 DM is by far the most common type of diabetes in adults
- predisposes to cardiovascular diseases
- In the US, DM is the leading cause of end-stage renal disease, nontraumatic lower extremity amputations, and adult blindness.
- Etiology involves complex interactions between environmental and genetic factors

Epidemiology



FIGURE 417-2 Worldwide prevalence of diabetes mellitus. Global estimate is 382 million individuals with diabetes. Regional estimates of the number of individuals with diabetes (20–79 years of age) are shown (2013). (Used with permission from the IDF Diabetes Atlas, the International Diabetes Federation, 2013.)

Harrison's principle of internal medicine (19th Ed)



At least 80% of people in Africa with diabetes are undiagnosed, and many in their 30s to 60s will die from diabetes there.

The greatest percentage increase in rates of diabetes will occur in Africa over the next 20 years.

Major risk factors

- Age > 45 years (may occur in young individuals)
- Obesity (BMI ≥25 kg/m2 or ethnically relevant definition for overweight)
- Physical inactivity
- Family history of type 2 diabetes in a first-degree relative (eg, parent or sibling)
- Race: panic, Native American, African American, Asian American, or Pacific Islander descent.
- History of previous impaired glucose tolerance (IGT) or impaired fasting glucose (IFG)

ADA: Diabetes Care 37(Suppl 1):S14,2014.

Major risk factors cont...


- Hypertension (>140/90 mm Hg) or dyslipidemia (HDL cholesterol level < 40 mg/dL or triglyceride level >150 mg/dL)
- History of gestational diabetes mellitus or of delivering a baby with a birth weight of over 4kg
- Polycystic ovarian syndrome (which results in insulin resistance)
- History of cardiovascular disease


ADA: Diabetes Care 37(Suppl 1):S14,2014

Pathogenesis: glucose metabolism

The pancreas releases insulin after eating to lower blood glucose. The actions of insulin are:

- (1) promotes glucose uptake by target cells (muscle, brain,...) and provides for glucose storage as glycogen,
- (2) prevents fat and glycogen breakdown and inhibits gluconeogenesis,
- (3) Increases protein synthesis





Effects of insulin deficiency

Metabolic defects

Carbohydrate Metabolism

 Diminished uptake of glucose by tissues such as muscle, adipose tissue and liver

2. Overproduction of glucose (via glycogenolysis and glyconeogenesis) by the liver

Protein Metabolism

1.Diminished uptake of amino and diminished synthesis of protein

2. Increased proteolysis

Fat Metabolism

1.Increased lipolysis 2.Decreased lipogenesis 3.Increased production of triglycerides

4.Decreased removal of ketones and increased ketone production

Elevated plasma and urine ketones

Chemical abnormalities

Hyperglycemia

Negative nitrogen balance

Elevated levels of branch chain amino acids Elevated blood urea nitrogen level Elevated potassium level

Elevated plasma fatty acids level Elevated plasma glycerol level Hypertriglyceridemia


Clinical abnormalities

Polyuria, polydipsia, polyphagia Blurred vision, Diminished mental alertness

> Loss of muscle mass Weakness

Loss of adipose tissue

Exudative xanthoma Lipemia retinalis Pancreatitis (abdominal pain) Hyperventilation metabolic acidosis



Criteria for the Diagnosis of Diabetes Mellitus

Symptoms of diabetes plus random blood glucose concentration $\geq 11.1 \text{ mmol/L} (200 \text{ mg/dL})$,

Or

Fasting plasma glucose \geq 7.0 mmol/L (126 mg/dL)

Or,

Hemoglobin A1c \geq 6.5%

Or,

2-h plasma glucose \geq 11.1 mmol/L (200 mg/dL) during an oral glucose tolerance test





Screening

a large number of individuals with DM are asymptomatic


➤type 2 DM may be present for up to a decade before diagnosis,

➤ complications at the time of their diagnosis,

treatment of type 2 DM may favorably alter the natural history of DM

The ADA recommends screening all individuals:

- >45 years every 3 years
- Early if overweight (BMI >25 kg/m2) and have one additional risk factor for diabetes



Complications

- Poorly controlled type 2 diabetes is associated with an array of complications.
- Diabetic complications:
 - Acute: diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar state(HHS), hypoglycemia
 - Longterm complications:
 - Microvascular: Retinopathy, Nephropathy (DKD), Neuropathy/diabetic foot
 - Macrovascular: Coronary, cerebral, and peripheral arterial disease

Hypoglycemia

As plasma glucose falls:

- \uparrow glucagon/epinephrine \rightarrow \uparrow CV stress
- \checkmark K+ \rightarrow Qt prolongs \rightarrow \uparrow Arrhythmia
- Endothelial dysfunction / ↑ PLT activation / ↑ blood viscosity → ↑ Thrombosis
- \checkmark brain fuel x 5-6 hrs $\rightarrow \uparrow$ Neuronal death

Outcomes are (much) worse with HYPOglycemia

50% \clubsuit mortality among outpatients with lowest Hgb A1c <6.5% vs A1c 7.5%

Diabetes Care 2011 May; 34(Supplement 2): S132-S137; Lancet 2010; 375: 481–89.

ADA Diagnostic Criteria for DKA and HHS

	DKA					
Parameter	Mild	Moderate	Severe	HHS		
Plasma glucose, mg/dL	>250	>250	>250	>600		
Arterial pH	7.25-7.3	7.0-7.24	<7.0	>7.30		
Serum bicarbonate, mmol/L	15-18	10 to <15	<10	>15		
Serum ketones [†]	Positive	Positive	Positive	Small		
Urine ketones [†]	Positive	Positive	Positive	Small		
Effective serum osmolality,* mOsm/kg	Variable	Variable	Variable	>320		
Alteration in sensoria or mental obtundation	Alert	Alert/drowsy	Stupor/coma	Stupor/coma		
*Calculation: 2[measured Na ⁺ (mEq/L)] + glucose (mg/dL)/18. [†] Nitroprusside reaction method.						

Macrovascular and microvascular complications.

Retinopathy

Leading cause of blindness in adults.

Accounts for - 24,000 cases of blindness every year.

Nephropathy

Leading cause of end-stage renal disease (ESRD) in the United States. Accounts for - 28,000 cases of ESRD every year.

Diabetes accounts for 1 of 3 patients with ESRD in the United States.

Myocardial Infarction and Stroke

Increased 2 to 4 fold.

Accounts for 60% to 70% of all diabetes-related deaths.

Peripheral Vascular Disease


Leading cause of nontraumatic amputations.

Accounts for ~ 67,000 limbs lost per year.

Three year survival is ~ 50%.

MANAGEMENT OF T2DM

Patient Exam



The goals of therapy

- (1) eliminate symptoms related to hyperglycemia,
- (2) reduce or eliminate the long-term microvascular and macrovascular complications of DM
- (3) allow the patient to achieve as normal a lifestyle as possible.


Symptoms of diabetes usually resolve when the plasma glucose is <11.1 mmol/L(200 mg/dL).

Glycemic goals for Nonpregnant Adults with Diabetes :ADA/EASD

- A1C : <7.0%
- Preprandial capillary plasma glucose: 80–130 mg/dL (4.4–7.2 mmol/L)
- Peak postprandial capillary plasma glucose: <180 mg/dL (<10.0 mmol/L)



Essential elements in comprehensive care of type 2 diabetes.



Diabetes self-management education(DSME) and support (DSMS).

- DSME/S are ways to improve the patient's knowledge, skills, and abilities necessary for diabetes self-care
- Four critical time points for DSME/S delivery:
 - At diagnosis
 - Annually for assessment of education, nutrition, and emotional needs
 - When new complicating factors arise that influence selfmanagement; and
 - When transitions in care occur

DSME/S

Education topics important for optimal diabetes care include:

- self-monitoring of blood glucose; urine ketone monitoring
- insulin administration;
- guidelines for diabetes management during illnesses;
- prevention and management of hypoglycemia
- foot and skin care;
- diabetes management before, during, and after exercise; and risk factor—modifying activities.

Medical nutrition therapy

- preventing or delaying the onset of type 2 DM in high-risk individuals (obese or with prediabetes) by promoting weight reduction. Medical treatment of obesity
- preventing or delaying diabetes-related complications in diabetic individuals by improving glycemic control.
- managing diabetes-related complications.
- the components of optimal MNT are similar for individuals with type 1 or type 2 DM and similar to those for the general population (fruits, vegetables, fiber-containing foods, and low fat)
- Weight loss and exercise improve insulin resistance.

Estimation of Food Portion Sizes

Your hands can be very useful in estimating portions. They're always with you, and they're always the same size! When planning a meal, the Canadian Diabetes Association suggests using these portion sizes as a guide:

How many vegetables? Choose as much as you can hold in both hands

How much grains & starches?

Choose an amount up to the size of your fist.



How much meat & alternatives

Choose an amount the size of your palm and the thickness of your little finger.



How much fruit? Choose an amount up to the size of your fist.



How much milk? Drink up to 1 cup or 250 ml of low-fat milk with a meal.

Physical activity

- Children with diabetes/prediabetes: at least 60 min/day physical activity.
- Adults:
 - 150+ min/wk of moderate-tovigorous activity over at least 3 nonconsecutive days/week
 - perform resistance training in 2-3 sessions/week on nonconsecutive days




Lifestyle change

• smoking cessation : Advise all patients not to use cigarettes, other tobacco products or e-cigarettes.


- Psychosocial care should be provided to all people with diabetes,
- Emotional well-being is an important part of diabetes care and self-management .

IDF treatment algorithm update



IDF Treatment Algorithm for People with Type 2 Diabetes. 2011

ADA/EASD Position Statement 2015



ADA, American Diabetes Association; DPP-4i, dipeptidyl peptidase-4 inhibitor; EASD, European Association for the Study of Diabetes; GLP-1RA, glucagon-like peptide-1 receptor agonist; HbA_{1c}, glycated haemoglobin; SGLT2i, sodium-glucose cotransporter 2 inhibitor; SU, sulphonylurea; TZD, thiazolidinedione Inzucchi SE et al. *Diabetes Care* 2015;38:140-149

Patient characteristics	Estimated total daily dose (units per kg)
Normal weight	0.4
Stage IV chronic kidney disease not on dialysis	0.25
Underweight, older age, or hemodialysis	0.3
Overweight	0.5
Obese, insulin resistant, or taking systemic glucocorticoids	≥ 0.6


NOTE: Glargine (Lantus) and detemir (Levemir) are the preferred agents, and glargine is favored because of its longer duration and once-per-day administration.³⁰

Information from references 7 and 30.



Am Fam Physician. 2017;96(10):648-654

Diabetes management considerations for individualized treatment: ADA/EASD Position Statement 2015



Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Hypertension/ Blood Pressure Control

- Patients with diabetes should be treated to a blood pressure <140/90 mmHg.
- Lower targets, such as <130/80 mmHg, may be appropriate for certain individuals at high risk of CVD, if they can be achieved without undue treatment burden.

Lifestyle intervention including:

- **D**healthy diet
- \Box Moderation of alcohol intake
- Increased physical activity

HTN...

- Treatment for hypertension should include
- \Box ACE inhibitor
- Angiotensin II receptor blocker (ARB)
- Thiazide-like diuretic
- Dihydropyridine calcium channel blockers

Multiple drug therapy (two or more agents at maximal doses) generally required to achieve BP targets.

Lipid Management

In adults a screening lipid profile is reasonable:

- At diabetes diagnosis
- At the initial medical evaluation
- And every 5 years, or more frequently if indicated

To improve lipid profile:

- Weight loss (if indicated)
- Reduction of saturated fat, trans fat, cholesterol intake
- Increase of ω -3 fatty acids, viscous fiber, plant stanols/sterols
- Increased physical activity

Table 9.1-Recommendations for statin and combination treatment in people with diabetes

Age	Risk factors	Recommended statin intensity*
<40 years	None	None
	ASCVD risk factor(s)**	Moderate or high
	ASCVD	High
40–75 years	None	Moderate
	ASCVD risk factors	High
	ASCVD	High
	ACS and LDL cholesterol ≥50 mg/dL (1.3 mmol/L) or in patients with a history of ASCVD who cannot tolerate high-dose statins	Moderate plus ezetimibe
>75 years	None	Moderate
	ASCVD risk factors	Moderate or high
	ASCVD	High
	ACS and LDL cholesterol ≥50 mg/dL (1.3 mmol/L) or in patients with a history of ASCVD who cannot tolerate high-dose statins	Moderate plus ezetimibe

*In addition to lifestyle therapy. **ASCVD risk factors include LDL cholesterol ≥100 mg/dL (2.6 mmol/L), high blood pressure, smoking, chronic kidney disease, albuminuria, and family history of premature ASCVD.

Antiplatlets therapy

- men or women with diabetes age ≥50 years who have at least one additional major risk factor, including:
 - Family history of premature ASCVD
 - Hypertension
 - Smoking
 - Dyslipidemia
 - Albuminuria
- Consider aspirin therapy (75–162 mg/day)
- As a primary prevention strategy in those with type 1 or type 2 diabetes at increased cardiovascular risk

Diabetic Retinopathy

- Prevent with good glycemic Control
- Exam at diagnosis, then every 2 years if normal
- If not normal: at least annually per ophthalmologist
- Classified into Proliferative and non proliferative
- Laser photocoagulation therapy is indicated to reduce the risk of vision loss in patients with high-risk PDR and, in some cases, severe NPDR.
- Retinopathy is not a contraindication to aspirin therapy for cardioprotection, as it does not increase the risk of retinal hemorrhage.

Diabetic kidney disease

- Defined by albuminuria or decreased GFR in absence of other cause of kidney disease
- Albuminuria: spot albumin: creatinine ratio
- Screening: Yearly
- Prevent Progression
 - ACE I or ARB strongly recommended for patients w/ urinary albumin excretion ≥300 mg/g creatinine and/or eGFR <60 ,
 - Control BP and Glycemia
- patients have eGFR <30, refer for evaluation for renal replacement treatment

Diabetic neuropathies

- =are a family of nerve disorders caused by diabetes.
- People with diabetes can, over time, develop nerve damage throughout the body.
- May be asymptomatic,
- Others may have symptoms such as pain, tingling, or numbness—loss of feeling—in the hands, arms, feet, and legs.
- Nerve problems can occur in every organ system, including the digestive tract, heart, and sex organs.
- Life time risk of **diabetic foot is 25%**

Diabetic neuropathies: Patient education

- Avoid smoking, walking barefoot.
- The feet should be inspected daily, looking between and underneath the toes and at pressure areas for skin breaks, blisters, swelling, or redness
- may be prevented with good glycemic control.
- It can be treated with gabapentin and/or amitryptiline, along with pain medicines.

Foot care

All patients with diabetes should have their feet inspected at every visit.

Provide general foot self-care education to all patients with diabetes.

A multidisciplinary approach is recommended for individuals with foot ulcers and high-risk feet.



Mental Health and DM

- Dementia
 - \uparrow 73% risk of all dementia, esp vascular dementia (\uparrow 127%)
- Increased risk of Anxiety
 - Worries about injecting, hypo/hyper glycemia
- Increased risk of Depression
 - Chronic Illness, stress
- Patients with schizophrenia high risk of T2DM
 - Screen yearly

Take home message

- T2 DM is by far the most common type of diabetes in adults
- Rates of diabetes are increasing worldwide
- The greatest percentage increase in rates of diabetes will occur in Africa over the next 20 years.
- T2DM results from a combination of peripheral insulin resistance and inadequate insulin secretion by pancreatic beta cells.
- Usually asymptomatic, need of screening.
- Poorly controlled T2DM is associated with an array of complications including end-stage renal disease, nontraumatic lower extremity amputations, and adult blindness.

Take home message

- The goal of therapy is to eliminate symptoms related to hyperglycemia, reduce or eliminate the long-term microvascular and macrovascular complications of DM, allow the patient to achieve as normal a lifestyle as possible
- Multi-disciplinary approach to address complications
- No one size fits all; individualized approach

